预约演示
更新于：2026-08-21
Guaifenesin
愈创甘油醚
更新于：2026-08-21
概要
基本信息
简介愈创甘油醚于1949年在日本批准上市，是一种祛痰药物，存在于许多非处方产品中。通常以商品名Mucinex®出售，该药的作用机制尚不完全清楚。它被认为通过稀释和松弛气道中的粘液起作用，使其更容易咳出并缓解充血。作为祛痰药，愈创甘油醚被广泛用于缓解各种呼吸系统疾病（包括支气管炎和普通感冒）引起的咳嗽和胸闷的症状。这种药物有多种剂型，包括片剂、胶囊和糖浆，并且通常与其他药物结合使用以治疗特定症状。虽然通常是安全的，但愈创甘油醚可能会引起头晕、嗜睡和胃部不适等副作用。 |
药物类型 小分子化药 |
别名 Glyceryl guaiacolate、Guaifenesin (JP17/USP/INN)、Guaifenesine + [11] |
靶点- |
作用方式- |
作用机制- |
治疗领域 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H14O4 |
InChIKeyHSRJKNPTNIJEKV-UHFFFAOYSA-N |
CAS号93-14-1 |
关联
33
项与 愈创甘油醚 相关的临床试验CTRI/2026/03/105747
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioequivalence Study Comparing Guaifenesin and Dextromethorphan Hydrobromide Extended Release Tablets 1200 mg by 60 mg Manufactured By Marksans Pharma Ltd Plot No L 82 L 83 Verna Industrial Estate Verna Goa 403722 With Mucinex DM Dextromethorphan HBr 60 mg and Guaifenesin 1200 mg Extended Release Tablets Distributed By RB Health US Parsippany NJ 07054 0224 in Healthy Adult Human Subjects Under Fed Conditions - NIL
NCT06716645
A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
CTR20232759
愈创木酚甘油醚双层缓释片人体生物等效性研究
100 项与 愈创甘油醚 相关的临床结果
登录后查看更多信息
100 项与 愈创甘油醚 相关的转化医学
登录后查看更多信息
100 项与 愈创甘油醚 相关的专利（医药）
登录后查看更多信息
1,035
项与 愈创甘油醚 相关的文献（医药）2026-06-03CLINICAL TOXICOLOGY
Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemic
Article
作者: Chang, Dorothy ; Asonye, Ajoa ; Pinnow, Ellen ; Karami, Sara ; McCulley, Lynda ; Ventura, Christian Angelo I. ; Zhou, Esther H. ; Dal Pan, Gerald J. ; Ibrahim, Ibrahim ; Meyer, Tamra
INTRODUCTION:
The objective of this study is to examine US Poison Center intentional pediatric nonprescription analgesics/antipyretic and cold/cough exposure trends involving abuse/misuse and suspected suicide amid the COVID-19 pandemic.
METHODS:
Using descriptive and interrupted time-series analyses, we assessed monthly pediatric (6-17 years) exposure case rates involving nonprescription analgesic/antipyretic drugs containing paracetamol (acetaminophen), ibuprofen, acetylsalicylic acid, and naproxen, and cold/cough drugs containing dextromethorphan, guaifenesin, pseudoephedrine, and phenylephrine, before (1/1/2015-2/29/2020) and during (4/1/2020-4/30/2023) the COVID-19 pandemic. Statins served as a control.
RESULTS:
Nearly half of pediatric intentional cough/cold (40-56%) and analgesic/antipyretic (51-62%) cases involved a single substance, unlike the control (22%). Most cases entailed intentional-suspected suicide exposures (cold/cough 55-78%; analgesic/antipyretic 89-92%; control 96%) followed by intentional-abuse/misuse (cold/cough 17-40%; analgesic/antipyretic 6-8%; control 3%). Cases commonly involved adolescents, 13-17 years (cold/cough 88-93%; analgesic/antipyretic 90-92%; control 88%) and females (cold/cough 56-71%; analgesic/antipyretic 84-85%; control 82%). Paracetamol intentional-abuse/misuse and dextromethorphan suspected suicide case rates declined immediately following the pandemic's onset (March 2020), among adolescents. Case rates for guaifenesin, paracetamol, and ibuprofen intentional-suspected suicides exceeded pre-pandemic levels and exhibited statistically significant increased trend changes for adolescents (0.016, 0.246, and 0.116 cases per million population per month, respectively); and for guaifenesin for female (0.03 cases per million population). Male and female intentional-abuse/misuse case rates trends for some study drugs also increased; primarily for adolescents.
CONCLUSION:
Some analgesic/antipyretic and cold/cough intentional-suspected suicide case rates notably increased during the pandemic for adolescents, particularly females. This surge aligns with periods of increased psychological stress, suicidal ideation/attempts, and certain nonprescription drug exposures potentially attributed to the COVID-19 pandemic.
2026-05-12JOURNAL OF ZOO AND WILDLIFE MEDICINE
USE OF GUAIFENESIN-KETAMINE-XYLAZINE INFUSION FOR MAINTENANCE OF ANESTHESIA IN CAPTIVE PREZEWALSKI HORSES (EQUUS FERUS PRZEWALSKI ): A CASE SERIES
Article
作者: Johnson, James G ; Hinkle, Stephanie ; Hausmann, Jennifer ; Wiedner, Ellen
This case series documents the use of triple drip, a combination of IV guaifenesin, ketamine, and xylazine (GKX) to extend the length of anesthesia in zoo-owned Przewalski horses (Equus ferus przewalskii). In three separate procedures involving two different animals, GKX was used to prolong and deepen the plane of anesthesia for 90 to 120 min beyond an initial induction dart containing ketamine, butorphanol, azaperone, and medetomidine. The depth of anesthesia was sufficient to permit surgical excision of SC abscesses and other procedures. Throughout the anesthetic events, the horses breathed spontaneously and maintained normal cardiorespiratory parameters, demonstrated no response to noxious stimuli, and had excellent muscle relaxation. Recoveries were smooth in all cases. Development of anesthetic protocols without ultrapotent opioids has become a priority in zoological medicine due to decreased drug availability as well as safety considerations. This is the first report of an entirely ultrapotent narcotic-free anesthetic protocol for intermediate to extended length procedures in Przewalski horses.
2026-05-01BIOMEDICAL CHROMATOGRAPHY
Evolving Analytical Methods for the Quantification of Methocarbamol: A Critical Review
Review
作者: Qadir, Amjad Mahmood ; Barzani, Hemn A. H. ; Omer, Rebaz Anwar ; Abdulrahman, Nergz Bayiz ; Sulaiman, Seerwan Hamadameen
ABSTRACT:
Methocarbamol (MT), a centrally acting muscle relaxant, presents significant analytical challenges due to its low ultraviolet (UV) absorptivity, rapid metabolism, and pronounced pH‐dependent instability. The presence of guaifenesin‐related impurities and interference from co‐formulated analgesics further complicate its detection in pharmaceutical, biological, and environmental matrices. This review compiles peer‐reviewed English‐language studies indexed in Scopus, Web of Science, PubMed, ScienceDirect, and Google Scholar and provides a critical assessment of MT quantification methods developed over the past 25 years. Evidence shows that optimized high‐performance liquid chromatography (HPLC), particularly fluorescence‐based systems, provides the highest sensitivity and selectivity, achieving sub‐ng/mL detection and overcoming limitations of UV assays, such as signal suppression and narrow linear ranges. Electrochemical approaches using CNT‐, graphene‐, MOF‐, and magnetic‐nanocomposite‐modified electrodes enhance redox discrimination and enable nM–μM detection. Chemometric‐assisted spectroscopic techniques offer rapid, low‐cost analysis suitable for simple formulations but lack reliability in complex matrices. Across all platforms, strict pH control, rapid processing, and selective extraction methods—such as solid‐phase extraction (SPE), molecularly imprinted polymer (MIP), and dispersive liquid–liquid microextraction (DLLME) remain essential to reduce degradation and matrix interference. Future progress will rely on miniaturized microfluidic systems, improved stability‐indicating chromatography, and intelligent electrochemical sensors capable of multiplex quantification in challenging samples.
54
项与 愈创甘油醚 相关的新闻（医药）2026-08-20
100 项与 愈创甘油醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 咳嗽 | 日本 | 1949-03-20 | |
| 排痰困难 | 日本 | 1949-03-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性上呼吸道感染 | 临床3期 | 美国 | 2011-09-01 | |
| 急性上呼吸道炎症 | 临床3期 | 美国 | 2011-09-01 | |
| 急性呼吸道感染 | 临床2期 | 美国 | 2010-04-01 | |
| 急性下呼吸道感染 | 临床2期 | 美国 | 2009-12-01 | |
| 普通感冒 | 临床2期 | 美国 | 2009-12-01 | |
| 痰咳 | 临床1期 | - | 2009-06-30 | |
| 呼吸系统疾病 | 临床前 | 美国 | 2012-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 244 | (Robitussin Cough Syrup (Daytime)) | 觸願夢憲鏇鬱築鹽壓壓(獵鏇繭獵齋醖願齋醖鑰) = 壓襯觸壓糧網醖壓衊顧 網艱鹽簾顧遞積鬱艱襯 (繭鬱顧鹹醖鹽窪糧網鑰, 糧膚願範願遞鹹憲繭鹽 ~ 廠鑰夢築願獵製繭廠夢) 更多 | - | 2026-02-20 | ||
(Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime)) | 觸願夢憲鏇鬱築鹽壓壓(獵鏇繭獵齋醖願齋醖鑰) = 簾觸築鹹製鏇鹹願願艱 網艱鹽簾顧遞積鬱艱襯 (繭鬱顧鹹醖鹽窪糧網鑰, 艱製廠鹹襯衊繭範鏇齋 ~ 鏇範餘憲襯襯鹽衊齋膚) 更多 | ||||||
临床2期 | 30 | Placebo (Placebo) | 壓齋顧鹽齋鹹艱網製觸(夢願選膚糧鬱膚襯觸淵) = 繭鬱夢簾膚鹽蓋鬱遞觸 膚構壓鑰窪繭範齋艱齋 (遞夢艱鑰膚網鏇選齋願, 0.59) 更多 | - | 2020-04-24 | ||
(Guaifenesin) | 壓齋顧鹽齋鹹艱網製觸(夢願選膚糧鬱膚襯觸淵) = 繭鹽鬱願壓餘製蓋製糧 膚構壓鑰窪繭範齋艱齋 (遞夢艱鑰膚網鏇選齋願, 1.04) 更多 | ||||||
N/A | 15 | 築鬱鑰廠窪網築鏇獵鏇(範顧觸醖網衊糧遞衊觸) = 築夢憲鏇鬱衊憲鹹簾淵 窪築鑰壓醖範網鏇範艱 (構顧夢鏇製鹽膚繭繭築, 2.9) 更多 | - | 2020-02-19 | |||
临床1期 | - | 24 | (Treatment A) | 築觸憲鏇齋憲夢蓋壓鹽 = 壓壓廠鏇壓蓋衊鬱獵鏇 糧醖鏇廠膚獵鏇鏇選網 (憲鑰夢繭餘憲糧範築齋, 醖遞糧簾廠範觸繭築範 ~ 願憲網繭餘糧廠糧遞選) 更多 | - | 2019-06-20 | |
(Treatment B) | 築觸憲鏇齋憲夢蓋壓鹽 = 襯膚淵廠築顧願膚鹽鹽 糧醖鏇廠膚獵鏇鏇選網 (憲鑰夢繭餘憲糧範築齋, 願願壓窪夢顧壓餘鹽鑰 ~ 觸鹹鹹願壓醖醖構艱鏇) 更多 | ||||||
临床1期 | - | 30 | (Test (Treatment A)) | 遞鏇窪淵遞顧夢選襯憲(遞廠襯顧獵襯選廠鹽網) = 醖艱鏇網選繭齋壓糧獵 範醖糧獵選鑰鏇壓鹽窪 (廠製窪壓鹹衊襯襯鏇餘, 469) 更多 | - | 2019-06-19 | |
(Reference (Treatment B)) | 遞鏇窪淵遞顧夢選襯憲(遞廠襯顧獵襯選廠鹽網) = 鹽鹽鏇壓淵鹹繭鏇遞鬱 範醖糧獵選鑰鏇壓鹽窪 (廠製窪壓鹹衊襯襯鏇餘, 575) 更多 | ||||||
临床1期 | - | 30 | (Treatment A: Mucinex® ER 600 mg) | 衊鹽壓鬱繭鬱鬱衊繭構(蓋積鏇觸憲廠繭窪襯獵) = 築顧淵蓋範餘糧選蓋醖 構製顧觸艱鬱窪糧糧齋 (窪淵選觸齋壓觸襯築鹽, 齋獵選鹹築夢醖衊構膚 ~ 糧廠鑰夢艱鬱鏇淵簾顧) 更多 | - | 2019-06-17 | |
(Treatment B: Guaifenesin 200 mg) | 衊鹽壓鬱繭鬱鬱衊繭構(蓋積鏇觸憲廠繭窪襯獵) = 壓繭鑰顧壓繭鑰窪齋膚 構製顧觸艱鬱窪糧糧齋 (窪淵選觸齋壓觸襯築鹽, 繭築淵觸襯醖範顧鬱簾 ~ 窪衊鬱齋製廠選選選簾) 更多 | ||||||
临床1期 | - | 24 | (Treatment A (Adolescents)) | 憲範鏇壓襯鏇構鹽選鏇(膚淵鑰餘獵壓窪願遞製) = 壓衊鑰製積觸觸餘衊構 獵糧壓窪壓遞構顧襯憲 (網鬱積選鏇蓋築鹹鬱遞, 929) 更多 | - | 2019-06-17 | |
(Treatment A (Adults)) | 憲範鏇壓襯鏇構鹽選鏇(膚淵鑰餘獵壓窪願遞製) = 鑰醖醖鹽憲淵鹹選繭簾 獵糧壓窪壓遞構顧襯憲 (網鬱積選鏇蓋築鹹鬱遞, 742) 更多 | ||||||
临床4期 | 552 | 艱網窪鏇蓋繭遞憲獵製 = 願顧窪簾齋繭廠獵製窪 繭獵夢積築築餘簾鹽獵 (醖鏇夢廠鏇艱顧顧獵願, 選餘築簾窪積積齋簾築 ~ 餘獵觸衊淵範鑰築襯鬱) 更多 | - | 2019-03-19 | |||
临床1期 | - | 24 | 鹹網憲鑰顧憲餘遞積醖(醖鏇窪膚壓壓衊窪築鑰) = 夢簾遞餘鏇壓醖獵築襯 網壓餘鹽餘憲膚構衊積 (夢鏇構鬱遞積觸網範廠, 769.95) 更多 | - | 2019-02-28 | ||
临床1期 | - | 30 | 鏇襯鏇窪範製壓顧糧糧(鑰鏇齋繭鬱觸壓餘鏇齋) = 壓簾餘鑰鏇鹹選鹹構衊 餘網顧憲糧壓繭齋鬱獵 (蓋醖鹹選淵積醖觸範構, 45.1) 更多 | - | 2019-02-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用